ASX Healthcare Stocks on Investor’s Radar: CSL (ASX:CSL), Pro Medicus (ASX:PME) and Telix Pharmaceuticals (ASX:TLX) Report Key Business Developments

Sonal Goyal

14 September 2026 08:39 PM AEST

ASX Healthcare Stocks on Investor’s Radar: CSL (ASX:CSL), Pro Medicus (ASX:PME) and Telix Pharmaceuticals (ASX:TLX) Report Key Business Developments

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

CSL (ASX:CSL), Pro Medicus (ASX:PME) and Telix Pharmaceuticals (ASX:TLX) operate across different areas of the healthcare sector, including plasma-derived therapies and vaccines, medical-imaging software and radiopharmaceuticals. During 2026, the three companies reported financial results alongside updates covering restructuring initiatives, new contracts, product development, regulatory activity and clinical programs.

CSL (ASX:CSL)

CSL operates through CSL Behring, CSL Seqirus and CSL Vifor, covering plasma-derived therapies, vaccines, iron-deficiency products and nephrology treatments. The company reports its financial results in USD and has a 30 June financial year-end.

For FY26, CSL reported total segment Revenue of USD 15.797 billion. Underlying NPATA attributable to CSL shareholders was USD 3.098 billion, compared with USD 3.219 billion in FY25. Cash Flow from operations reached USD 3.512 billion.

CSL (ASX:CSL) reported a statutory net loss attributable to shareholders of USD 2.579 billion for FY26. The statutory result included restructuring and Impairment expenses, with total impairment expenses of USD 7.079 billion recognised during the year. CSL Vifor accounted for USD 4.845 billion of these impairment expenses, while CSL Behring and CSL Seqirus recorded USD 1.256 billion and USD 715 million, respectively.

Pro Medicus (ASX:PME)

Pro Medicus develops medical-imaging software through its Visage platform, which is used by hospitals and radiology organisations to manage, view and distribute medical images. Its operations include radiology imaging, digital pathology and other imaging applications.

For FY26, Pro Medicus reported revenue of AUD 261.7 million, an increase of 22.9%. Underlying EBIT reached AUD 196.1 million, while underlying NPAT was AUD 144.7 million. Reported NPAT was AUD 265.3 million. The company remained debt-free and held AUD 252.3 million in cash and other financial Assets at the end of the period.

Pro Medicus (ASX:PME) reported an underlying EBIT Margin of 74.9% for FY26. On a constant-currency basis, underlying revenue was AUD 273.5 million, underlying EBIT was AUD 206.0 million and underlying NPAT was AUD 154.5 million.

Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals develops and commercialises radiopharmaceutical products for cancer imaging and treatment. Its commercial portfolio includes prostate cancer imaging products Illuccix and Gozellix, while the company is also advancing therapeutic and precision-medicine development programs.

For the six months ended 30 June 2026, Telix reported group revenue of USD 477 million, an increase of 22% year over year. Group gross margin was 55%, while adjusted EBITDA reached USD 52 million. Profit after tax was USD 38 million.

Research and development expenditure was USD 124 million during the first half, with Investment directed primarily towards late-stage therapeutic and precision-medicine programs. Telix Pharmaceuticals (ASX:TLX) generated USD 23 million in Operating Cash Flow and held USD 252 million in cash at 30 June 2026.

2026 Healthcare Developments

CSL's FY26 disclosures covered USD 15.797 billion of segment revenue, underlying NPATA attributable to shareholders of USD 3.098 billion, restructuring activity and impairment expenses recorded across several Business units.

Pro Medicus reported FY26 revenue of AUD 261.7 million and underlying NPAT of AUD 144.7 million, alongside AUD 407 million of new contracts and product development across its medical-imaging software portfolio.

Telix reported H1 2026 revenue of USD 477 million, adjusted EBITDA of USD 52 million and profit after tax of USD 38 million while continuing commercialisation and clinical development across its radiopharmaceutical portfolio.

FAQs

Q: What did CSL report for FY26?

A: CSL reported total segment revenue of USD 15.797 billion and underlying NPATA attributable to shareholders of USD 3.098 billion. The company also recorded significant restructuring and impairment expenses during FY26.

Q: What were Pro Medicus' main FY26 figures?

A: Pro Medicus reported AUD 261.7 million in revenue, AUD 196.1 million in underlying EBIT and AUD 144.7 million in underlying NPAT. It also signed new contracts worth at least AUD 407 million.

Q: What did Telix Pharmaceuticals report for H1 2026?

A: Telix reported USD 477 million in group revenue, USD 52 million in adjusted EBITDA and USD 38 million in profit after tax for the six months ended 30 June 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.